Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

NCT04155749

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Advanced Cellular Therapeutics Facility, DCAM 0800A Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Froedtert Hospital/Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Active, Not Recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024

Conditions
Blood Protein Disorders, COVID-19, COVID-19 Infection, +30 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Johns Hopkins University Baltimore, Maryland, United States
  • U Mass Chan Medical School Worcester, Massachusetts, United States
  • SUNY-Stony Brook Stony Brook, New York, United States
View Trial Details
Active, Not Recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • HonorHealth Cancer Transplant Institute Scottsdale, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

NCT04221178

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
View Trial Details
Active, Not Recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Alfred Hospital Melbourne, Australia
  • University Hospital Leuven Leuven, Belgium
  • University Hospital Ostrava Ostrava, Czechia
  • Odense University Hospital Odense, Denmark
View all 13 locations
View Trial Details
Active, Not Recruiting

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber at Brighton Brighton, Massachusetts, United States
  • Dana-Farber at Merrimack Valley Methuen, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

NCT03933735

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680 San Francisco, California, United States
  • Tulane University School of Medicine /ID# 242322 New Orleans, Louisiana, United States
  • Mayo Clinic - Rochester /ID# 238683 Rochester, Minnesota, United States
  • Washington University-School of Medicine /ID# 238681 St Louis, Missouri, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

NCT04624906

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Vancouver General Hospital Vancouver, British Columbia, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View Trial Details

Related conditions